Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab Treat-to-Target in Ulcerative Colitis
NCT02425865Phase 4Completed
- Sponsor
- GETAID
- Start
- Dec 2016
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 4 trial of golimumab in ulcerative colitis (UC), sponsored by GETAID. Started Dec 2016; status: completed.
02
Drugs
golimumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02425865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02425865.